Eight of the Biggest Immunology and Inflammation (I&I) Deals in 2025
In 2025 the immunology and inflammation sector saw eight blockbuster partnerships, each worth between $1.7 billion and $4 billion. Deals ranged from AstraZeneca’s $175 million upfront, $4.4 billion‑potential collaboration with Harbour BioMed to Vor Bio’s surprising $4 billion licensing of telitacicept despite a massive wind‑down. Other highlights include Gilead‑LEO Pharma’s $1.7 billion oral STAT6 program, Sanofi’s $1.8 billion bispecific antibody pact with Earendil, and AbbVie’s $1.64 billion molecular‑glue agreement with Neomorph. Collectively, the agreements underscore a shift toward multi‑specific biologics, oral small molecules and precision degraders to tackle autoimmune and chronic inflammatory diseases.
Biotech in 2025: A Retrospective
2025 marked a phase shift in biotech as metabolic health, AI, and radiopharmaceuticals moved from hype to mainstream impact. GLP‑1 and related incretin drugs expanded into broader cardiometabolic indications, with over 40 candidates in development and major licensing deals reshaping...
Lisbon Is Calling: The BIO-Europe Startup Spotlight Returns in March 2026
BIO‑Europe’s Startup Spotlight, the premier European biopharma pitch competition, announced its 2025 champion, German spin‑out Fusix Biotech, which secured the trophy in Vienna with its InFUSE chimeric oncolytic virus platform. The contest selects eight early‑stage companies—fewer than 25 employees and...
Keep an Eye on These 15 Biotech Companies in 2026
Labiotech’s 2026 "biotechs to watch" list spotlights fifteen companies across gene therapy, cell therapy, base editing, radiopharma and metabolic disease, each with pivotal clinical or regulatory milestones slated for the coming year. Highlights include AAVantgarde’s $141 million Series B and proof‑of‑concept trials...
Fifteen Gift Ideas for a Biotech Enthusiast This Holiday Season
The article curates fifteen holiday gift ideas tailored for biotechnology enthusiasts, ranging from playful items like the Viral board game to advanced tools such as portable DNA sequencers. It highlights novelty products—including glow‑in‑the‑dark mushrooms, DNA‑shaped cookie cutters, and personalized DNA...
Tackling Pulmonary Fibrosis: Boehringer Ingelheim’s New Drug + AI Approach
Boehringer Ingelheim has launched the first new pulmonary‑fibrosis medicine in more than a decade, an oral PDE4B inhibitor that secured FDA approval and will be rolled out globally. The company also introduced eLung, an AI‑driven imaging tool that spots microscopic...
